WASHINGTON (Reuters) - As scientists and pharmaceutical companies work at breakneck speed to develop a vaccine for the novel coronavirus, public health officials and senior U.S. lawmakers are sounding alarms about the Trump administration’s lack of planning for its nationwide distribution.
The federal government traditionally plays a principal role in funding and overseeing manufacturing and distribution of new vaccines during pandemics, which often draw on scarce ingredients and need to be made, stored and transported carefully.
There won't be enough vaccine for all 330 million Americans right away, so the government also has a role in deciding who gets it first, and in educating a vaccine-wary here public about its potential life saving merits.
Right now, it is unclear who in Washington is in charge of oversight, much less any critical details, some state health officials and members of Congress told Reuters.
The federal government traditionally plays a principal role in funding and overseeing manufacturing and distribution of new vaccines during pandemics, which often draw on scarce ingredients and need to be made, stored and transported carefully.
There won't be enough vaccine for all 330 million Americans right away, so the government also has a role in deciding who gets it first, and in educating a vaccine-wary here public about its potential life saving merits.
Right now, it is unclear who in Washington is in charge of oversight, much less any critical details, some state health officials and members of Congress told Reuters.
